Daily FNArena News - Australia

Biopharmaceutical company Opthea is poised to undertake two phase-3 trials for its treatment to improve vision for those affected by macular degeneration

The summer ahead promises better crop returns for agribusiness Elders, which is integrating several acquisitions and expanding market share.

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Ramsay Health Care does not expect a substantial increase in activity going forward, amid a subdued recovery in Australian surgical admissions. Europe is unlikely to contribute to earnings growth in FY21.

Computershare’s first quarter update received mixed responses, with several issues required to pan out positively to achieve FY21 guidance.

What are Deterra Royalties? Well, the recently-listed stock offers a unique ASX exposure to iron ore, taking a royalty stream from BHP Group’s Mining Area C.

As outages for maintenance in the year ahead create challenges for Incitec Pivot this should be countered by improved fertiliser prices and a recovery in demand for explosives.

The setting will not get any easier for Macquarie Group in the second half as transaction activity remains low, yet the business is poised for upside in FY22 as a welter of investment opportunities become available.

Delays in the timing of new deals and a softer outlook for services revenue has undermined short-term confidence in Fineos Corp.

Following the exit of the major banks from wealth management, specialist providers have stepped up but are likely to endure several years of increasing competition in price and technology.